Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

1193 – Use of DNA Profiling to Resolve Discrepant HIV Tests in the Setting of Injectable Cabotegravir PrEP

Background In clinical trials, discordant test results can complicate participant management and study endpoint determination. HIV diagnosis can be challenging when long-acting cabotegravir (CAB-LA) is used for HIV pre-exposure prophylaxis (PrEP) since HIV antigen, antibody, and RNA levels are often low. HIV assays can also revert from reactive/positive to non-reactive/negative in this setting. We evaluated…

1180 – Engaging Male Partners of HIV-Negative Pregnant Women in HIV Testing Using Oral HIV Self-Test

Background Women are at risk of acquiring HIV throughout the perinatal period. HIV testing uptake among the male partners remains low thus the couple are often unaware of the male partner’s HIV status. The antenatal setting, with nearly universal uptake of HIV testing for women, can also serve as a way of reaching male partners. However, the optimal…

1184 – Impact of a New Opt-In Targeted Strategy for HIV Testing in Emergency Departments

Background To analyze the time trends of HIV testing in Barcelona (Spain) and investigate if emergency departments (EDs) have changed HIV screening patterns and if the implementation of an opt-in targeted strategy for HIV testing in these EDs impacted these trends. Methods Between 2017-2023 (7 years), monthly HIV tests performed in 4 hospitals covering a…

1230 – PURPOSE 1: Preference for Twice-Yearly Injection vs Daily Oral Pills for HIV PrEP in Cisgender Women

Background Although oral pre-exposure prophylaxis (PrEP) is effective for HIV prevention, its routine use in cisgender women remains low. Effectiveness is contingent on high adherence and persistence post initiation, which many cite as a barrier for daily oral pills. In the Phase 3 PURPOSE 1 trial, twice-yearly subcutaneous (SC) lenacapavir (LEN) was safe and 100% efficacious in…

1203 – Patterns of Choice, Switching, and Discontinuation of Oral and Injectable PrEP Among Adolescents

Background Long-acting injectable PrEP (LAI-PrEP) offers a promising alternative for adolescents from sexual and gender minorities (ASGM), as adherence to oral PrEP is a challenge for this population. This study examines patterns of choice and switching between oral and LAI-PrEP among ASGM in Brazil. Methods PrEP15-19 Choices is an implementation study offering oral and LAI-PrEP…

1208 – Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England

Background In 2022, a global outbreak of mpox occurred among gay and bisexual men who have sex with men (GBMSM). In England, the outbreak was controlled through reductions in sexual risk behaviour and vaccination of high-risk GBMSM. However, mpox continues to circulate, including an expanding outbreak in Africa, and so there is a risk of future outbreaks…

1213 – Oral Fluid Concentrations of Tenofovir and Emtricitabine for Antiretroviral Adherence Monitoring

Background Adherence monitoring using drug concentrations for oral Pre-exposure Prophylaxis (PrEP) can identify people who need additional adherence support interventions or a transition to long-acting injectable regimens. Oral fluids are widely accepted as a convenient and confidential specimen type for HIV self-testing. This study evaluated the feasibility of detecting emtricitabine (FTC) and tenofovir (TFV) in…

1214 – Are Sex-Specific Cutoffs Needed With a Next-Gen Urine Tenofovir Assay for Adherence Monitoring?

Background Females may require higher oral Pre-exposure Prophylaxis (PrEP) adherence to achieve equivalent therapeutic drug concentrations compared to males, suggesting the need for sex-specific cutoffs for rapid urine tenofovir (TFV) assays. We developed a next-gen urine TFV Lateral Flow Assay (LFA) without a predefined threshold to (1) determine if the quantified LFA readouts differ between females…

1219 – Impact of Initiation Delay, Duration, and Prior PrEP Usage on FTC/TDF-Containing PEP Efficacy

Background Pre- and post-exposure prophylaxis (PrEP and PEP) are key strategies to prevent HIV infection. While the efficacy of PrEP has been elucidated in many randomized clinical trials, corresponding data for PEP is challenging to obtain in a controlled setting. Consequently, it is almost impossible to study the impact of PEP initiation delay and PEP…

1221 – Cost-Effectiveness of Different Risk-Group Targeting Across 3 Types of PrEP in Zimbabwe

Background Oral pre-exposure prophylaxis (oral PrEP) has long been part of the HIV prevention portfolio in Zimbabwe. The introduction of long-acting, injectable PrEP (LA PrEP) in 2022 and the dapivirine vaginal ring (ring PrEP) in 2023 have the potential to increase PrEP uptake and further reduce HIV incidence in Zimbabwe. However, the impact and optimal…